Company intelligence / Profile preview

Vela Pharmaceuticals

Iselin/Lawrenceville, New Jersey, USAveladx.com ↗

Ownership: Private
Development stage: Commercial

Overview

Vela Pharmaceuticals was a privately held biotech/pharma company focused on developing medicines targeting diseases of the nervous system, especially those involving the brain-gut axis. Its lead asset, R-tofisopam, showed positive Phase II results in irritable bowel syndrome. The company also had assets targeting depression and additional preclinical candidates. In March–April 2006 it was acquired by Pharmos Corporation in a deal valued at approximately $29.7 million.

Therapeutic areas: GastroenterologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Tofisopam

Unknown

Partnerships

Otsuka Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on Vela Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vela Pharmaceuticals.

Explore the full profile